SHARE

GSK nears $1bn deal for biotech drug

The UK drugmaker is close to a $1bn deal to buy US biotech IDRx, which is developing a treatment for rare gastrointestinal tumours. It is conducting early-stage trials of its targeted therapy for patients with cancer called gastrointestinal stromal tumour.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.